Viser 1 - 50 av 128 resultater
Tid Selskap Tittel Sektor Kategori
19 Dec 2024
09:37 CET
ULTIMOVACS Ultimovacs ASA: Notice of extraordinary general meeting on 9 January 2024 - CORRECTION 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
19 Dec 2024
07:00 CET
ULTIMOVACS Ultimovacs ASA: Notice of extraordinary general meeting on 9 January 2024 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
18 Dec 2024
08:00 CET
ULTIMOVACS ULTI - EX. RIGHT TO PARTICIPATE IN POTENTIAL REPAIR OFFERING TODAY 20103010 Biotechnology Ex Date
17 Dec 2024
19:39 CET
ULTIMOVACS Key information relating to the potential subsequent repair offering to be carried out by Ultimovacs ASA 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
17 Dec 2024
19:24 CET
ULTIMOVACS Ultimovacs ASA - Mandatory notification of trade  20103010 Biotechnology Mandatory notification of trade primary insiders
17 Dec 2024
17:53 CET
ULTIMOVACS ULTIMOVACS ANNOUNCES AGREEMENT TO COMBINE ITS BUSINESS WITH ZELLUNA IMMUNOTHERAPY AND INTENTION TO LAUNCH FULLY COMMITTED PRIVATE PLACEMENT 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
06 Nov 2024
07:00 CET
ULTIMOVACS Ultimovacs ASA Reports Third Quarter 2024 Financial Results and Provides General Business Update 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
31 Oct 2024
07:00 CET
ULTIMOVACS Ultimovacs ASA: Invitation to third quarter 2024 results webcast presentation 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
25 Oct 2024
17:00 CEST
ULTIMOVACS Ultimovacs Announces Publication of Phase II FOCUS Trial Results on medRxiv 20103010 Biotechnology Non-regulatory press releases
11 Sep 2024
17:00 CEST
ULTIMOVACS Ultimovacs Announces Patient Recruitment Discontinuation in LUNGVAC Trial Investigating UV1 Combined with Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
09 Sep 2024
00:10 CEST
ULTIMOVACS Ultimovacs Announces Updated Data Analysis on UV1 Phase II NIPU Trial in Mesothelioma at ESMO 2024 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
21 Aug 2024
07:00 CEST
ULTIMOVACS Ultimovacs ASA Reports Second Quarter 2024 Financial Results and Provides General Business Update 20103010 Biotechnology Half yearly financial reports and audit reports/limited reviews
15 Aug 2024
07:00 CEST
ULTIMOVACS Ultimovacs ASA: Invitation to second quarter 2024 results webcast presentation 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
07 Aug 2024
13:59 CEST
ULTIMOVACS Ultimovacs Announces Notice of Resignation from Deputy Board Member 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
05 Aug 2024
19:12 CEST
ULTIMOVACS Ultimovacs Announces Topline Data from FOCUS Phase II Trial of UV1 Combined with Pembrolizumab in Patients with Metastatic or Recurrent Head and Neck Cancer 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
01 Aug 2024
17:20 CEST
ULTIMOVACS Ultimovacs Announces Poster Presentation of NIPU Phase II Trial Update at Upcoming ESMO Congress 2024 20103010 Biotechnology Non-regulatory press releases
24 Jun 2024
21:00 CEST
ULTIMOVACS Ultimovacs ASA announces revised terms of the employee share option program 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
11 Jun 2024
07:00 CEST
ULTIMOVACS Ultimovacs provides update from Phase I study in malignant melanoma: Continued strong overall survival in patients treated with UV1 cancer vaccine and pembrolizumab 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
01 Jun 2024
14:15 CEST
ULTIMOVACS Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting 20103010 Biotechnology Non-regulatory press releases
07 May 2024
07:00 CEST
ULTIMOVACS Ultimovacs ASA Reports First Quarter 2024 Financial Results and Provides General Business Update 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
30 Apr 2024
07:00 CEST
ULTIMOVACS Ultimovacs ASA: Invitation to first quarter 2024 results webcast presentation 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
24 Apr 2024
16:14 CEST
ULTIMOVACS Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting 20103010 Biotechnology Non-regulatory press releases
18 Apr 2024
14:42 CEST
ULTIMOVACS Ultimovacs ASA - Annual General Meeting held on April 18, 2024 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
16 Apr 2024
22:10 CEST
ULTIMOVACS Ultimovacs Implements Operational Adjustments to Support Continuous Advancement of the UV1 Vaccine Phase II Program 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
15 Apr 2024
07:00 CEST
ULTIMOVACS Ultimovacs ASA - Disclosure of voting rights of Annual General Meeting 20103010 Biotechnology Total number of voting rights and capital
09 Apr 2024
20:00 CEST
ULTIMOVACS Ultimovacs - Invitation to Business Update on April 17, 2024 20103010 Biotechnology Non-regulatory press releases
04 Apr 2024
07:00 CEST
ULTIMOVACS Ultimovacs to Present Poster at the American Association for Cancer Research (AACR) Annual Meeting 2024   20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
25 Mar 2024
07:00 CET
ULTIMOVACS Ultimovacs ASA: Notice of Annual General Meeting on April 18, 2024 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
22 Mar 2024
13:27 CET
ULTIMOVACS Ultimovacs ASA: Mandatory notification of trade by primary insider 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
21 Mar 2024
07:00 CET
ULTIMOVACS Ultimovacs ASA: Annual Report 2023 20103010 Biotechnology Annual financial and audit Reports
09 Mar 2024
11:00 CET
ULTIMOVACS Ultimovacs ASA: Mandatory notification of trades by primary insider 20103010 Biotechnology Mandatory notification of trade primary insiders
08 Mar 2024
23:00 CET
ULTIMOVACS Ultimovacs ASA: Mandatory notification of trades by primary insider 20103010 Biotechnology Mandatory notification of trade primary insiders
08 Mar 2024
08:13 CET
ULTIMOVACS Ultimovacs ASA – Mandatory trade notification and disclosure of holding 20103010 Biotechnology Major shareholding notifications
07 Mar 2024
23:00 CET
ULTIMOVACS Ultimovacs ASA: Mandatory notification of trade by primary insiders 20103010 Biotechnology Mandatory notification of trade primary insiders
07 Mar 2024
16:37 CET
ULTIMOVACS Ultimovacs ASA – Disclosure of shareholding 20103010 Biotechnology Major shareholding notifications
07 Mar 2024
11:26 CET
ULTIMOVACS Ultimovacs ASA – Disclosure of shareholding 20103010 Biotechnology Major shareholding notifications
07 Mar 2024
07:00 CET
ULTIMOVACS Ultimovacs Announces Topline Results from INITIUM Study Evaluating UV1 Vaccination Added to Ipilimumab and Nivolumab in Patients with Unresectable or Metastatic Malignant Melanoma 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
02 Mar 2024
18:41 CET
ULTIMOVACS Ultimovacs announces publication of results from NIPU Phase II trial with UV1 vaccination in mesothelioma in European Journal of Cancer 20103010 Biotechnology Non-regulatory press releases
19 Feb 2024
07:00 CET
ULTIMOVACS Ultimovacs Receives EMA Orphan Drug Designation for UV1 Cancer Vaccine for the Treatment of Mesothelioma   20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
14 Feb 2024
07:00 CET
ULTIMOVACS Ultimovacs ASA Reports Fourth Quarter 2023 Financial Results and Provides General Business Update 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
08 Feb 2024
08:00 CET
ULTIMOVACS Ultimovacs ASA: Invitation to fourth quarter 2023 results webcast presentation 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
05 Feb 2024
07:00 CET
ULTIMOVACS Ultimovacs Receives FDA Fast Track Designation for UV1 Cancer Vaccine for the Treatment of Patients with Unresectable Mesothelioma 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
16 Jan 2024
07:00 CET
ULTIMOVACS Ultimovacs Updates Timeline for Reporting on Randomized UV1 Phase II Trial INITIUM in Malignant Melanoma; Topline Results expected in March 2024   20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
04 Jan 2024
18:57 CET
ULTIMOVACS Ultimovacs ASA: Mandatory notification of trade by primary insider 20103010 Biotechnology Mandatory notification of trade primary insiders
02 Jan 2024
19:25 CET
ULTIMOVACS Ultimovacs ASA: Mandatory notification of trade by primary insider 20103010 Biotechnology Mandatory notification of trade primary insiders
19 Dec 2023
16:51 CET
ULTIMOVACS Ultimovacs ASA: Mandatory notification of trade by primary insider 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
18 Dec 2023
08:39 CET
ULTIMOVACS Financial calendar 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
18 Dec 2023
07:00 CET
ULTIMOVACS Ultimovacs Announces Completion of Exploratory Phase I TENDU Study of TET Vaccine Technology Platform Meeting the Primary Endpoint 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
28 Nov 2023
07:00 CET
ULTIMOVACS Ultimovacs Announces Resignation of Aitana Peire from Board of Directors 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
21 Nov 2023
17:00 CET
ULTIMOVACS Ultimovacs ASA: Mandatory notification of trade by primary insider 20103010 Biotechnology Mandatory notification of trade primary insiders